Lucid Diagnostics (LUCD) Earnings Date & Reports

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

LUCD is expected to report earnings to fall 2.63% to -18 cents per share on May 19

Lucid Diagnostics LUCD Stock Earnings Reports

Q1'25

Est.

$-0.19

Q4'24

Missed

by $0.02

Q3'24

Beat

by $0.01

Q2'24

Est.

$-0.20

Q1'24

Beat

by $0.04

The last earnings report on March 24 showed earnings per share of -18 cents, missing the estimate of -17 cents. With 313.48K shares outstanding, the current market capitalization sits at 42.94M.

View a ticker or compare two or three

Compare

LUCD